Design Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Design Therapeutics, Inc. (DSGN) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $13.50 per share as of 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Notes
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2023-03-14
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $13.50.
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $15.60.
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $5.08.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2022-12-31 | $13.50 10-K · filed 2023-03-14 |
| 2021-12-31 | $15.60 10-K · filed 2023-03-14 |
| 2020-12-31 | $5.08 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |